INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10656450	
Filing Date		2003-09-05	
First Named Inventor	Inventor BRUNICARDI, F. Charles		
Art Unit		1632	
Examiner Name	Sgagias, M.K.		
Attorney Docket Number		023698-002US	

/MS/	1	SHALEV et al., "Suicide gene therapy for prostate cancer using a replication-deficient adenovirus containing the herpesvirus thymidine kinase gene," WORLD J. UROL (2000), Vol. 18, pp. 125-129								
/MS/	2	NAGAMACHI et al., "Suicidal gene therapy for pleural metastasis of lung cancer by liposome-mediated transfer of herpes simplex virus thymidine kinase gene," CANCER GENE THERAPY (1999), Vol. 6, No. 6, pp. 546-553								
/MS/	3		AOKI et al., "Gene Therapy for Peritoneal Dissemination of Pancreatic Cancer by Liposome-Mediated Transfer of Herpes Simplex Virus Thymidine Kinase Gene," HUMAN GENE THERAPY (1997), Vol. 8, pp. 1105-1113							
/MS/	4	BLOCK, et al., "Adenoviral-Mediated Herpes Simplex Virus Thymidine Kinase Gene Transfer: Regression of Hepatic Metastasis of Pancreatic Tumors," PANCREAS (1997), Vol. 15, No. 1, pp. 25-34								
/MS/	5	MAKINEN et al., "Evaluation of herpes simplex thymidine kinase mediated gene therapy in experimental pancreatic cancer," THE JOURNAL OF GENE MEDICINE (2000), Vol. 2, pp. 361-367								
If you wis	h to a	dd addit	tional non-patent literature document citation	information please click the Add b	utton Add					
			EXAMINER SIG	GNATURE						
Examiner	Sign	ature	/Magdalene Sgagias/	Date Considered	07/02/2007					
			eference considered, whether or not citation nance and not considered. Include copy of t							
Standard S ⁴ Kind of do	T.3). ³ cument	For Japan t by the ap	Patent Documents at www.USPTO.GOV or MPEP 901 lesse patent documents, the indication of the year of the propriate symbols as indicated on the document under is attached.	reign of the Emperor must precede the seri	al number of the patent do	cument.				